acut
cellular
reject
affect
greater
third
lung
transplant
recipi
alloreact
lymphocyt
respond
directli
indirectli
donor
antigen
constitut
basi
lung
allograft
reject
diagnos
wellestablish
histopatholog
criteria
reflect
sever
perivascular
peribronchi
inflamm
lung
allograft
recent
evid
support
complex
immun
respons
allograft
involv
humor
mechan
character
circul
antibodi
donor
hla
specif
pattern
lung
injuri
occur
parallel
cellbas
reject
emerg
evid
suggest
interact
recipi
genet
immunosuppress
therapi
allograft
environment
exposur
includ
pulmonari
infect
contribut
high
reject
rate
lung
transplant
greater
understand
heterogen
mechan
lung
reject
critic
develop
effect
therapi
target
precis
pathophysiolog
diseas
ultim
improv
longterm
lung
transplant
outcom
acut
allograft
reject
remain
preval
seriou
problem
lung
transplant
incid
first
year
post
transplant
accord
latest
report
registri
intern
societi
heart
lung
transplant
ishlt
although
acut
lung
reject
rare
fatal
indirect
consequ
consider
advers
effect
transplant
outcom
treatment
acut
reject
increas
immunosuppress
increas
risk
mani
post
transplant
infect
furthermor
despit
treatment
cellular
humor
reject
constitut
major
risk
factor
bronchiol
obliteran
syndrom
bo
bo
condit
progress
airflow
obstruct
thought
reflect
manifest
chronic
lung
transplant
reject
post
transplant
death
beyond
first
year
occur
directli
indirectli
result
bo
compar
solid
organ
lung
appear
particularli
high
risk
reject
although
reason
entir
clear
increas
lung
vulner
earli
ischem
injuri
recurr
infect
constant
environment
exposur
might
contribut
high
rate
lung
reject
review
present
immunolog
basi
acut
lung
allograft
reject
describ
clinic
patholog
featur
acut
cellular
vascular
agrad
reject
acut
cellular
airway
bgrade
reject
also
known
lymphocyt
bronchiol
figur
addit
discuss
emerg
understand
import
humor
reject
lung
transplant
focus
role
antihuman
leukocyt
antigen
hla
antibodi
present
develop
de
novo
transplant
figur
highlight
current
strategi
prevent
treatment
cellular
humor
allograft
reject
absenc
immunosuppress
transplant
recipi
develop
robust
respons
allograft
predominantli
driven
tcell
recognit
foreign
major
histocompat
complex
mhc
protein
call
human
leukocyt
antigen
hla
human
foreign
mhc
express
transplant
tissu
cell
first
present
directli
recipi
tcell
donor
dendrit
cell
graft
direct
pathway
donor
antigen
present
cell
apc
die
destroy
recipi
dendrit
cell
process
present
alloantigen
recipi
tcell
indirect
pathway
hla
gene
locat
short
arm
human
chromosom
tradit
divid
two
class
base
histor
differenti
classic
hla
class
gene
includ
b
cw
loci
express
nucleat
cell
classic
hla
class
ii
gene
includ
dr
dq
dp
gene
express
constitut
bcell
monocyt
dendrit
cell
apc
upregul
varieti
cell
inflammatori
condit
extraordinari
divers
hla
polymorph
creat
consider
barrier
transplant
donor
organ
quickli
recogn
nonself
basi
hla
differ
recipi
common
pathway
acut
cellular
reject
involv
recruit
activ
recipi
lymphocyt
predominantli
effector
tcell
lung
allograft
result
allograft
injuri
loss
function
consequ
success
outcom
lung
transplant
becom
possibl
widespread
introduct
clinic
practic
calcineurin
inhibitor
cyclosporin
permit
highli
effect
blockad
tcell
activ
prolifer
howev
spite
intens
tcell
suppress
strategi
lung
transplant
patient
continu
experi
high
rate
reject
process
allorecognit
like
augment
local
innat
immun
activ
endogen
tissu
injuri
exogen
infect
innat
immun
activ
promot
alloantigen
present
costimul
tcell
activ
humor
respons
follow
lung
transplant
recent
appreci
due
advent
modern
highli
sensit
solid
phase
antibodydetect
techniqu
clear
patient
present
transplant
preform
antihla
antibodi
usual
acquir
prior
pregnanc
transfus
transplant
immun
stimul
prior
infect
autoimmun
might
contribut
develop
antibodi
allomhc
patient
identifi
risk
factor
preexist
antibodi
react
donor
antigen
lead
immedi
graft
loss
hyperacut
reject
acceler
humor
reject
bo
addit
lung
transplant
recipi
appear
mount
humor
respons
allograft
transplant
evid
suggest
humor
respons
occur
donor
mhc
antigen
although
endotheli
epitheli
antigen
express
lung
may
becom
antibodi
target
well
tcell
activ
indirect
present
provid
help
bcell
memori
antibodi
class
switch
affin
matur
presenc
appropri
cytokin
costimulatori
factor
acut
chronic
humor
reject
well
describ
renal
transplant
furthermor
histolog
featur
antibodymedi
reject
found
lung
biopsi
absenc
measur
antihla
antibodi
precis
immun
mechan
complex
interact
lead
stimul
cellular
humor
immun
ultim
lung
reject
remain
fulli
elucid
nevertheless
acut
cellular
reject
acut
humor
reject
result
vascular
injuri
presenc
antihla
antibodi
process
overlap
clinic
may
potenti
figur
acut
lung
allograft
reject
asymptomat
time
patholog
diagnosi
present
symptom
rang
dyspnea
cough
sputum
product
acut
respiratori
distress
exam
find
may
includ
fever
hypoxia
adventiti
sound
lung
auscult
nonspecif
natur
symptom
sign
emphasi
place
object
data
mainli
pulmonari
function
test
identifi
patient
risk
reject
spirometri
found
sensit
greater
detect
infect
reject
grade
higher
differenti
two
radiograph
imag
lung
transplant
patient
use
identifi
specif
caus
symptom
decreas
pulmonari
function
focal
infect
neoplasm
find
groundglass
opac
septal
thicken
volum
loss
pleural
effus
highresolut
chest
ct
scan
suggest
acut
reject
although
earli
small
studi
attempt
demonstr
use
chest
xray
chest
ct
scan
diagnosi
reject
recent
data
show
low
sensit
acut
reject
low
discriminatori
valu
reject
process
given
poor
specif
pulmonari
function
test
radiograph
studi
discourag
empir
treatment
reject
recommend
histopatholog
analysi
lung
tissu
diagnos
grade
acut
lung
reject
incid
acut
reject
highest
within
first
year
post
transplant
argu
high
clinic
suspicion
time
period
bronchoscopi
bronchoalveolar
lavag
bal
transbronchi
biopsi
import
diagnost
modal
acut
allograft
reject
consid
lung
transplant
recipi
allograft
dysfunct
allow
acut
reject
distinguish
potenti
etiolog
allograft
dysfunct
airway
stenosi
infect
transbronchi
biopsi
perform
lower
lobe
practic
seem
reason
light
data
show
differ
lung
lobe
similar
reject
grade
reject
present
grade
usual
wors
lower
lobe
compar
upper
lobe
lung
reject
studi
group
lrsg
recommend
piec
wellexpand
alveol
lung
parenchyma
provid
adequ
sensit
diagnos
reject
advers
event
report
bronchoscopi
lung
transplant
recipi
rel
low
includ
transient
hypoxemia
bleed
clinic
signific
pneumothorax
arrhythmia
possibl
postprocedur
pneumonia
ventil
support
report
mortal
widespread
agreement
benefit
clinicallydirect
bronchoscopi
lung
transplant
role
surveil
bronchoscopi
asymptomat
patient
remain
disput
mani
center
perform
schedul
bronchoscopi
month
month
month
annual
posttranspl
addit
clinicallyind
postreject
followup
bronchoscopi
rational
includ
occurr
clinic
silent
acut
reject
inadequ
surrog
marker
acut
reject
rel
low
risk
bronchoscopi
procedur
grade
higher
acut
reject
found
asymptomat
patient
occasion
presenc
late
onset
acut
reject
beyond
one
year
post
transplant
disput
approach
one
group
show
outcom
patient
underw
clinicallyind
bronchoscopi
compar
underw
surveil
bronchoscopi
well
ishlt
databas
outcom
random
trial
would
help
determin
benefit
surveil
bronchoscopi
lung
transplant
recipi
attempt
obviat
need
surveil
biopsi
mani
report
focus
less
invas
surrog
acut
lung
reject
multipl
studi
assess
bal
cell
protein
possibl
correl
acut
reject
mani
studi
small
replic
acut
reject
associ
elev
tcell
activ
tcell
activ
nk
cell
elev
interferongamma
bal
pilot
studi
gene
express
bal
fluid
lung
transplant
recipi
found
gene
express
signatur
relat
tlymphocyt
function
cytotox
activ
neutrophil
degranul
correl
acut
reject
addit
studi
need
valid
find
establish
whether
bal
microarray
determin
acut
reject
signatur
costeffect
provid
inform
supplement
replac
biopsi
result
even
attract
studi
noninvas
mean
diagnos
acut
reject
without
bronchoscopi
although
effect
serum
biomark
current
use
clinic
lung
transplant
mani
studi
hepatocyt
growth
factor
shown
correl
acut
reject
small
singlecent
studi
cylex
immun
cell
function
assay
immuknow
cylex
inc
columbia
md
approv
us
food
drug
administr
measur
global
immun
function
solid
organ
transplant
recipi
assay
measur
invitro
product
adenosin
triphosph
atp
patient
peripher
blood
tcell
respons
stimul
phytohemagglutininl
sever
studi
kidney
liver
heart
small
bowel
allograft
recipi
demonstr
low
atp
level
ngml
correl
infect
high
level
ngml
associ
reject
two
studi
evalu
assay
lung
transplant
recipi
demonstr
low
atp
level
correl
infect
associ
acut
reject
assess
preliminari
data
publish
abstract
form
show
lung
reject
episod
occur
set
low
moder
atp
level
addit
exhal
breath
analysi
studi
shown
promis
result
exhal
nitric
oxid
correl
lymphocyt
bronchiol
acut
reject
studi
inert
ga
singl
breath
washout
slope
alveolar
plateau
helium
sensit
acut
reject
summari
surrog
marker
suffici
valid
mean
reproduc
identifi
patient
acut
reject
adequ
specif
none
supplant
direct
histopatholog
examin
lung
tissu
nevertheless
studi
arena
like
provid
valuabl
inform
underli
mechan
reject
better
explain
clinic
heterogen
diseas
histolog
appear
acut
lung
allograft
reject
grade
rule
acut
cellular
reject
agrad
airway
inflamm
bgrade
chronic
airway
reject
bronchiol
obliteran
cgrade
chronic
vascular
reject
acceler
graft
vascular
sclerosi
dgrade
outlin
work
formul
publish
lung
reject
studi
group
lrsg
workshop
organ
ishlt
grade
scheme
key
featur
summar
tabl
illustr
imag
institut
shown
figur
typic
agrad
acut
cellular
reject
lung
allograft
manifest
perivascular
mononuclear
inflammatori
cell
infiltr
without
interstiti
mononuclear
cell
major
mononuclear
cell
tcell
preponder
cell
although
studi
describ
increas
popul
bcell
eosinophil
increas
thick
mononuclear
cell
cuff
around
vessel
increas
mononuclear
invas
interstiti
alveolar
space
determin
agrad
tabl
figur
intraread
agreement
acut
reject
found
good
kappa
interread
reliabl
grade
scheme
rang
good
suboptim
kappa
high
low
confound
featur
concurr
infect
alveolar
damag
earli
post
transplant
may
addit
blur
pictur
contribut
interread
pathologist
discord
gener
lrsg
recommend
grade
reject
exclus
infect
bgrade
airway
mononuclear
inflamm
clearli
part
spectrum
acut
cellular
reject
figur
f
grade
remain
inconsist
due
frequent
lack
airway
tissu
biopsi
suscept
tissu
artifact
confound
concurr
infect
due
low
inter
reader
reliabl
prior
grade
schema
bgrade
reject
lrsg
simplifi
bgrade
grade
tabl
nomenclatur
use
grade
noncartilagin
small
airway
rigor
exclus
infect
multipl
studi
demonstr
acut
reject
major
risk
factor
develop
chronic
airflow
obstruct
singl
episod
acut
reject
well
increas
frequenc
sever
acut
reject
increas
risk
bo
area
controversi
signific
minim
acut
reject
solitari
perivascular
infiltr
earli
year
lung
transplant
reject
usual
discount
treat
studi
sinc
found
minim
acut
reject
grade
increas
risk
subsequ
highergrad
reject
grade
subsequ
bo
untreat
solitari
perivascular
monocyt
infiltr
may
lead
worsen
acut
reject
furthermor
base
multipl
studi
grade
b
lymphocyt
bronchiol
also
known
import
risk
factor
bo
death
independ
acut
vascular
reject
although
lymphocyt
inflamm
frequent
seen
endobronchi
biopsi
larg
cartilagin
airway
clinic
prognost
signific
remain
unclear
demonstr
link
lymphocyt
inflamm
seen
endobronchi
biopsi
lymphocyt
bronchiol
bronchiti
seen
transbronchi
biopsi
although
eosinophil
bcell
mast
cell
identifi
acut
reject
biopsi
correl
wors
prognosi
exact
clinic
signific
remain
unclear
mani
risk
factor
acut
lung
allograft
reject
studi
focu
found
signific
categor
allorecognitionrel
immunosuppressionrel
recipientrel
infecti
allorecognitionrelatedit
gener
thought
intens
host
alloimmun
respons
relat
recipi
recognit
differ
donor
antigen
process
drive
acut
lung
allograft
reject
consist
idea
sever
singlecent
studi
shown
increas
degre
hla
mismatch
especi
hladr
hlab
hlaa
loci
increas
risk
acut
reject
addit
ishlt
registri
data
show
correl
hla
match
well
gendermatch
surviv
although
well
understood
multiorgan
transplant
gener
believ
provid
immunolog
advantag
lead
lower
rate
reject
due
dampen
allorecognit
high
burden
foreign
hla
antigen
decreas
reject
shown
graft
kidney
liver
heart
combin
heartkidney
liverkidney
heartlung
transplant
recipi
although
benefit
seem
translat
prolong
graft
recipi
surviv
data
regard
lung
reject
presenc
second
organ
remain
inconclus
immunosuppressionrelatedwhil
clear
adequ
immunosuppress
necessari
lung
allograft
mainten
optim
regimen
defin
sever
studi
suggest
may
lower
incid
acut
reject
tacrolimu
oppos
cyclosporin
one
random
doubleblind
trial
show
decreas
reject
everolimu
oppos
azathioprin
self
report
ishlt
registri
data
support
idea
decreas
acut
reject
episod
tacrolimu
mmf
compar
cyclosporin
azathioprin
surprisingli
studi
directli
examin
link
level
immunosuppress
acut
reject
high
titer
epsteinbarr
viru
ebv
peripher
blood
surrog
marker
high
overal
level
immunusuppress
found
correl
lower
incid
acut
reject
furthermor
one
episod
earli
highgrad
acut
reject
appear
predict
addit
acut
reject
episod
within
first
year
post
lung
transplant
suggest
aggress
immunosuppress
use
patient
recipientrelatedgenet
polymorph
also
consid
potenti
independ
risk
factor
reject
genotyp
lead
increas
product
may
protect
acut
reject
multi
drug
resist
genotyp
appear
predispos
treatmentresist
acut
reject
copi
number
variat
chemokin
gene
associ
suscept
acut
reject
addit
develop
pursu
hypothesi
genet
variat
innat
pattern
recognit
receptor
modul
develop
acut
reject
lung
transplant
regard
found
reduc
acut
reject
associ
variant
toll
like
receptor
blunt
innat
immun
respons
increas
reject
variant
augment
innat
respons
although
studi
suggest
polymorph
variant
outsid
hla
region
also
influenc
risk
acut
reject
larger
multicent
effort
need
fulli
valid
find
also
test
genegen
geneenviron
interact
among
relev
polymorph
collect
genet
studi
provid
consider
support
overal
hypothesi
constant
interplay
environ
pulmonari
innat
immun
modul
adapt
alloimmun
lung
transplant
consist
paradigm
gastroesophag
reflux
diseas
also
associ
increas
rate
acut
reject
furthermor
discuss
reject
also
appreci
follow
number
respiratori
infect
effect
age
acut
reject
appear
bimod
lowest
incid
acut
reject
infanc
age
increas
risk
childhood
compar
adulthood
incid
acut
reject
older
lung
transplant
recipi
age
higher
appear
similar
younger
adult
rate
infect
appear
higher
potenti
contribut
increas
mortal
howev
studi
need
determin
true
effect
age
reject
strategi
reduc
immunosuppress
advoc
older
recipi
infectiousinfecti
etiolog
given
lot
attent
potenti
adapt
immun
solid
organ
transplant
viral
infect
long
thought
modul
immun
system
heighten
alloreact
inde
high
incid
acut
reject
found
lung
transplant
recipi
follow
communityacquir
respiratori
tract
infect
rhinoviru
parainfluenza
viru
influenza
viru
human
metapneumoviru
coronaviru
respiratori
syncyti
viru
rsv
although
respiratori
virus
appear
associ
acut
reject
acut
phase
infect
studi
role
herpesvirus
polyomavirus
conduct
evid
associ
acut
reject
date
studi
directli
link
cmv
infect
cmv
prophylaxi
strategi
acut
reject
inconsist
recent
random
trial
cmv
prophylaxi
identifi
correl
cmv
incid
acut
reject
rate
one
studi
bacteri
infect
chlamydia
pneumonia
link
develop
acut
reject
bo
treatment
acut
lung
allograft
reject
consist
increas
immunosuppress
clear
consensu
grade
highergrad
reject
episod
requir
treatment
howev
light
recent
evid
grade
reject
lymphocyt
bronchiol
major
risk
factor
bo
treatment
seem
prudent
entiti
well
mainstay
treatment
acut
lung
reject
puls
steroid
sever
studi
show
success
resolut
improv
acut
reject
highdos
steroid
treatment
data
clearli
guid
dose
puls
steroid
standard
dose
mg
methylprednisolon
intraven
although
center
use
dose
rang
mg
per
day
mg
per
day
durat
treatment
also
vari
typic
includ
least
three
dose
follow
oral
prednison
taper
respons
steroid
variabl
earli
posttranspl
reject
seem
respond
better
late
reject
major
challeng
lung
transplant
treatment
persist
recurr
reject
repeat
cours
corticosteroid
one
option
sever
studi
support
switch
cyclosporin
tacrolimu
treatment
persist
acut
reject
mani
center
use
altern
immunosuppress
agent
polyclon
antithymocyt
globulin
atg
antagonist
recent
report
demonstr
util
alemtuzumab
monoclon
antibodi
treatment
refractori
acut
reject
small
cohort
patient
previous
fail
treatment
atg
therapi
consid
includ
inhal
cyclosporin
extracorpor
photopheresi
total
lymphoid
irradi
relationship
acut
reject
current
treatment
eventu
occurr
bo
area
consider
interest
although
acut
reject
appear
major
risk
factor
bo
remain
unclear
treatment
impact
longterm
allograft
function
patient
surviv
antibodymedi
allograft
reject
increasingli
recogn
entiti
lung
transplant
earli
observ
base
phenomenon
hyperacut
reject
preexist
donorspecif
antibodi
lead
complement
activ
rapid
graft
loss
advent
improv
crossmatch
pre
transplant
incid
hyperacut
reject
organ
decreas
howev
acut
chronic
antibodymedi
lung
reject
emerg
controversi
subject
develop
improv
antibodi
detect
identif
techniqu
allograftspecif
antibodi
implic
acut
chronic
kidney
well
heart
reject
recent
data
expand
concept
lung
transplant
mechan
antibodi
promot
lung
allograft
injuri
remain
poorli
understood
antibodi
bind
allomhc
endotheli
epitheli
target
lung
could
lead
activ
complement
cascad
complement
deposit
lead
endotheli
cell
injuri
product
proinflammatori
fibroblaststimul
molecul
recruit
inflammatori
cell
well
increas
gene
express
subsequ
prolifer
potenti
contribut
gener
oblit
airway
lesion
section
discuss
emerg
issu
humor
lung
reject
includ
humor
sensit
lung
transplant
well
patholog
featur
humor
reject
occur
without
presenc
detect
antibodi
serum
origin
methodolog
hla
serolog
type
antibodi
screen
identif
direct
crossmatch
complement
depend
cytotox
cdc
assay
assay
base
specif
reactiv
serum
antibodi
cell
surfac
antigen
activ
complement
caus
cell
death
identifi
microscop
use
vital
dye
cell
stain
cdc
assay
replac
institut
sensit
specif
solidphas
technolog
use
solid
matrix
coat
purifi
hla
antigen
obtain
either
cell
line
recombin
technolog
assay
abil
detect
complementfix
antibodi
noncomplementfix
antibodi
screen
antibodi
usual
achiev
flow
cytometri
use
panel
popul
bead
coat
hla
antigen
extract
individu
donor
figur
assay
determin
panel
reactiv
antibodi
pra
percentag
bead
lymphocyt
given
panel
recogn
patient
antihla
antibodi
patient
pra
determin
posit
actual
hla
specif
recipi
antihla
antibodi
determin
use
singl
antigen
bead
assay
bead
coat
recombin
hla
singl
antigen
recent
develop
solid
phase
methodolog
singl
antigen
detect
luminex
singl
antigen
bead
array
assay
simultan
detect
maximum
differ
color
bead
suspens
differ
hla
antigen
bound
color
bead
figur
spite
technolog
advanc
antibodi
may
still
present
level
detect
sensit
methodolog
andor
antigen
repres
screen
reagent
howev
believ
antibodi
remain
undetect
current
method
mostli
weak
antibodi
may
clinic
relev
nevertheless
definit
compat
test
remain
realtim
crossmatch
recipi
serum
potenti
donor
cell
flow
crossmatch
wherebi
actual
donor
cell
incub
recipi
serum
bound
antibodi
tag
secondari
fluoresc
antiigg
antibodi
proven
time
sensit
cdc
crossmatch
one
major
goal
donor
select
avoid
hla
antigen
potenti
recipi
preform
antibodi
lung
transplant
recipi
presensit
hla
antigen
antibodydetect
technolog
identifi
unaccept
donor
antigen
avoid
time
transplant
donor
becom
avail
inform
donor
hla
antigen
recipi
antibodi
compar
constitut
virtual
crossmatch
allow
realtim
prospect
crossmatch
waiv
virtual
crossmatch
approach
significantli
shorten
wait
time
presensit
recipi
correl
highli
crossmatch
result
perform
time
transplant
high
number
antihla
antibodi
significantli
decreas
donor
pool
increas
wait
time
lung
transplant
candid
instanc
intervent
remov
decreas
product
antibodi
may
consid
prior
transplant
discuss
even
though
unaccept
antigen
avoid
virtual
crossmatch
patient
posit
pre
transplant
pra
ie
circul
antihla
antibodi
higher
risk
post
transplant
complic
post
transplant
pra
remain
stabl
increas
via
gener
either
donorspecif
nondonorspecif
antihla
antibodi
similarli
patient
neg
pra
screen
test
pre
transplant
develop
de
novo
nondonorspecif
donorspecif
antihla
antibodi
post
transplant
use
modern
sensit
antibodi
detect
techniqu
recent
studi
consist
demonstr
increas
incid
acut
reject
persist
reject
increas
bo
wors
overal
surviv
patient
antihla
antibodi
effect
appar
pre
transplant
hla
sensit
well
develop
de
novo
donorspecif
antihla
antibodi
posttransplant
import
donor
specif
target
antigen
humor
reject
well
understood
risk
poor
outcom
may
heighten
set
donorspecif
antibodi
posit
retrospect
crossmatch
howev
patient
posit
pra
neg
crossmatch
without
specif
mismatch
donor
hla
antigen
also
found
increas
risk
poor
outcom
one
hand
nondonor
specif
antibodi
present
might
cross
react
donor
hla
antibodi
specif
donor
hla
might
rapidli
absorb
lung
allograft
preclud
detect
sera
altern
nonhla
antibodi
could
contribut
graft
injuri
exampl
de
novo
autoimmun
post
lung
transplant
type
v
collagen
tubulin
express
airway
epitheli
cell
shown
predispos
bo
anoth
studi
demonstr
presenc
antiendotheli
antibodi
direct
donor
antigen
absenc
antihla
antibodi
remain
unclear
exactli
often
post
transplant
pra
measur
extent
humor
reject
occur
among
lung
transplant
recipi
addit
research
need
precis
defin
signific
antibodi
donor
hla
third
parti
hla
selfantigen
lung
transplant
although
uncommon
due
use
crossmatch
screen
hyperacut
reject
caus
preexist
recipi
antibodi
donor
hla
antigen
describ
hyperacut
reject
usual
occur
within
hour
transplant
manifest
acut
pulmonari
decompens
profound
hypoxemia
diffus
pulmonari
edema
alveolar
hemorrhag
patient
may
respond
aggress
antihumor
therapi
mortal
high
recent
concept
acut
distinct
hyperacut
humor
reject
occur
later
week
year
posttranspl
cours
evolv
howev
notion
specif
histopatholog
syndrom
associ
acut
humor
reject
remain
controversi
posttranspl
vascular
injuri
pulmonari
capillar
describ
atyp
form
reject
may
resist
steroid
sever
case
respons
plasmapheresi
suggest
may
repres
antibodymedi
process
clinic
present
form
pulmonari
capillar
typic
includ
dyspnea
hypoxemia
pulmonari
infiltr
chest
xray
mimick
acut
cellular
reject
frank
hemoptysi
reflect
underli
diffus
alveolar
hemorrhag
describ
subset
recipi
antibodymedi
capillar
prompt
consider
entiti
recent
studi
attempt
evalu
immunoglobulin
complement
deposit
subendotheli
space
possibl
manifest
antibodymedi
reject
septal
capillari
deposit
immunoglobulin
complement
product
figur
well
elev
bal
describ
associ
circul
antihla
antibodi
similar
patholog
find
also
identifi
set
treatmentresist
cellular
reject
decreas
pulmonari
function
test
bo
howev
studi
found
evid
antibodi
deposit
complement
activ
set
allograft
reject
vascular
injuri
other
demonstr
stain
occur
lung
transplant
patient
nonalloimmun
lung
injuri
infect
pgd
evid
antihla
antibodi
although
stain
appear
independ
risk
factor
bo
differ
stain
techniqu
laboratori
subject
interpret
result
pathologist
may
explain
inconsist
publish
data
lrsg
report
work
formul
diagnosi
lung
reject
remain
cautiou
defin
patholog
appear
humor
reject
consensu
capillari
injuri
detect
lung
allograft
biopsi
figur
although
nonspecif
find
find
small
vessel
injuri
intim
endotheli
along
immunohistochem
demonstr
complement
deposit
rais
suspicion
acut
humor
reject
although
patholog
find
report
without
evid
circul
antihla
antibodi
visa
versa
presenc
one
patient
circul
antihla
antibodi
characterist
patholog
find
seen
strong
evid
acut
humor
reject
plasmapheresi
mainstay
antibodi
remov
circul
shown
lead
clinic
improv
lung
transplant
recipi
pulmonari
capillar
unrespons
steroid
howev
usual
reserv
sever
case
suspect
humor
reject
given
rel
invas
cumbersom
natur
intraven
immunoglobulin
ivig
one
common
therapi
use
decreas
antibodymedi
immun
rel
low
side
effect
profil
ivig
caus
bcell
apoptosi
reduc
bcell
number
block
bind
donorreact
antibodi
may
inhibit
complement
activ
peritranspl
use
ivig
plasmapheresi
institut
presensit
patient
led
elimin
antibodi
patient
class
antihla
antibodi
patient
class
ii
antihla
antibodi
group
presensit
patient
receiv
regimen
demonstr
signific
decreas
acut
reject
episod
trend
toward
greater
freedom
bo
compar
cohort
presensit
patient
receiv
desensit
therapi
rituximab
monoclon
antibodi
caus
bcell
deplet
proven
effect
treatment
presensit
renal
transplant
recipi
conjunct
ivig
recent
studi
lung
transplant
recipi
newli
acquir
posttranspl
donorspecif
antibodi
regimen
ivig
combin
rituximab
patient
administ
alon
patient
led
clear
antibodi
notabl
freedom
bo
surviv
better
group
patient
clear
donorspecif
antibodi
persist
antibodi
bortezomib
select
inhibitor
proteosom
caus
plasma
cell
apoptosi
new
therapi
proven
use
revers
alloantibodi
mediat
reject
renal
transplant
recipi
use
lung
transplant
describ
one
case
report
despit
new
highli
sensit
measur
screen
antihla
antibodi
evid
antibodi
detriment
allograft
optim
monitor
treatment
paramet
humor
reject
benefit
preemptiv
strategi
deplet
antibodi
remain
uncertain
studi
need
determin
whether
ivig
plasmapheresi
rituximab
bortezomib
alter
risk
chronic
allograft
dysfunct
sensit
patient
acut
cellular
reject
affect
greater
third
lung
transplant
recipi
alloreact
lymphocyt
respond
directli
indirectli
donor
antigen
constitut
basi
lung
allograft
reject
diagnos
wellestablish
histopatholog
criteria
reflect
sever
perivascular
peribronchi
inflamm
lung
allograft
recent
evid
supportsa
complex
immun
respons
allograft
involv
humor
mechan
character
circul
antibodi
donor
hla
specif
pattern
lung
injuri
occur
parallel
cellbas
reject
emerg
evid
suggest
interact
recipi
genet
immunosuppress
therapi
allograft
environment
exposur
includ
pulmonari
infect
contribut
high
reject
rate
lung
transplant
greater
understand
heterogen
mechan
lung
reject
critic
develop
effect
therapi
target
precis
pathophysiolog
diseas
ultim
improv
longterm
lung
transplant
outcom
venn
diagram
repres
relationship
acut
cellular
reject
gradea
gradeb
humor
reject
manifest
presenc
antihla
antibodi
histolog
find
flow
cytometr
antibodi
screen
measur
panel
reactiv
antibodi
pra
flowpra
bead
coat
purifi
hla
antigen
incub
patient
serum
subsequ
stain
fitclabel
antihuman
igg
flowpra
bead
analyz
flow
cytomet
bead
antibodi
bind
greater
fluoresc
intens
repres
rightward
channel
shift
compar
neg
control
percentag
valu
pra
calcul
base
area
peak
shift
patient
demonstr
pra
hla
class
hla
class
ii
multipl
peak
posit
flow
histogram
due
differ
bead
popul
emit
fluoresc
differ
intens
neg
control
refer
use
serum
standard
graphic
represent
luminex
singl
antigen
sa
bead
assay
result
detect
specif
antihla
antibodi
sa
bead
number
list
red
xaxi
sa
bead
coat
multipl
copi
singl
recombin
hla
antigen
mean
fluoresc
intens
mfi
repres
strength
antibodybind
bead
plot
yaxi
color
bar
repres
score
antibodi
reactiv
strength
specif
hla
antigen
test
list
gray
chart
graph
patient
posit
antibodi
reactiv
assign
bead
base
cutoff
establish
laboratori
therefor
patient
specif
antibodi
hla
dqa
antigen
encod
allel
presenc
antibodi
antigen
encod
allel
exclud
base
neg
reactiv
bead
also
carri
chainsantigen
encod
allel
